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Abstract
Background: Equine herpesvirus type 1 (EHV-1) induces respiratory infection, abortion, and neurologic disease with
significant impact. Virulence factors contributing to infection and immune evasion are of particular interest. A potential
virulence factor of the neuropathogenic EHV-1 strain Ab4 is ORF2.
This study on 24 Icelandic horses, 2 to 4 years of age, describes the infection with EHV-1 Ab4, or its deletion mutant
devoid of ORF2 (Ab4ΔORF2) compared to non-infected controls (each group n = 8). The horses’ clinical presentation,
virus shedding, viremia, antibody and cellular immune responses were monitored over 260 days after experimental
infection.
Results: Infection with Ab4ΔORF2 reduced fever and minimized nasal virus shedding after infection compared to the
parent virus strain Ab4, while Ab4ΔORF2 established viremia similar to Ab4. Concurrently with virus shedding, intranasal
cytokine and interferon α (IFN-α) production increased in the Ab4 group, while horses infected with Ab4ΔORF2
expressed less IFN-α.
The antibody response to EHV-1 was evaluated by a bead-based multiplex assay and was similar in both infected groups,
Ab4 and Ab4ΔORF2. EHV-1 specific immunoglobulin (Ig) G1 was induced 8 days after infection (d8 pi) with a peak on
d10–12 pi. EHV-1 specific IgG4/7 increased starting on d10 pi, and remained elevated in serum until the end of the study.
The intranasal antibody response to EHV-1 was dominated by the same IgG isotypes and remained elevated in both
infected groups until d130 pi. In contrast to the distinct antibody response, no induction of EHV-1 specific T-cells was
detectable by flow cytometry after ex vivo re-stimulation of peripheral blood mononuclear cells (PBMC) with EHV-1 in any
group. The cellular immune response was characterized by increased secretion of IFN-γ and interleukin10 in response to
ex vivo re-stimulation of PBMC with EHV-1. This response was present during the time of viremia (d5–10 pi) and was
similar in both infected groups, Ab4 and Ab4ΔORF2.
Conclusions: ORF2 is a virulence factor of EHV-1 Ab4 with impact on pyrexia and virus shedding from the nasal mucosa.
In contrast, ORF2 does not influence viremia. The immunogenicity of the Ab4ΔORF2 and parent Ab4 viruses are identical.
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Background
Equine herpesvirus type 1 (EHV-1), an alphaherpesvirus, fre-
quently induces clinical disease in horses and other equids.
Clinical manifestations include upper respiratory tract disease
with pyrexia as well as late-term abortions, or neurologic dis-
ease (equine herpesvirus myeloencephalopathy, EHM) [1–4].
EHV-1 is transmitted from horse to horse during close con-
tact via respiratory secretions. The virus initially infects the
epithelium of the upper respiratory tract. Subsequently, it
spreads through the underlying connective tissue to the re-
gional lymphoid tissues, and next establishes cell-associated
viremia in leukocytes [5–8]. Viremia is a prerequisite for the
infection of endothelial cells by EHV-1 and induction of vas-
culitis in the pregnant uterus or central nervous system.
These events can lead to the severe manifestations of EHV-1,
abortions or EHM, respectively [1, 3, 5, 9–11]. Furthermore,
EHV-1 establishes latency. Latent EHV-1 is believed to reside
in the trigeminal ganglia and in lymphoid tissues of the re-
spiratory tract [12–16].
Latency and immune evasion are two important charac-
teristics of EHV-1 preventing EHV-1 elimination by the
immune system of the horse. Latently infected horses
serve as a reservoir of the virus. EHV-1 can be reactivated
with or without signs of clinical disease in the reservoir
horse [17]. Lack of vaccination and incomplete protection
after vaccination provide sufficient susceptible hosts
within the population for EHV-1 to spread periodically
after reactivation from latency or from newly infected
horses [4, 17]. The prevalence of EHV-1 is high with de-
tection in 54–88% of horses post mortem [14, 18, 19].
Outbreaks of EHV-1 associated clinical disease occur in
variable frequencies but the severity of EHV-1 manifesta-
tions seems to be increasing [4, 14, 20]. Consequently,
EHV-1 has a significant impact on animal health and the
equine economy worldwide and EHM has been classified
as an emerging disease in the USA [20, 21]. Management
practices and biosecurity measures are applied to contain
EHM outbreaks. Many horses are regularly vaccinated in
order to prevent infection and disease. However, the use
of inactivated or attenuated live virus vaccines has not
been sufficient to completely protect from EHV-1 infec-
tion and outbreaks [22, 23]. Protective immune responses
after vaccination with available vaccines and after natural
infection in horses are transient and re-infection is pos-
sible between 4 and 8 weeks post vaccination or 6–
18 months post infection of adult horses [22, 24–27].
Recent research has focused on the identification of
EHV-1 virulence factors such as the mutation of the DNA
polymerase gene (ORF30) at nucleotide position 2554,
which has been associated with the manifestation of EHM
and the establishment of latency after EHV-1 infection.
Strains of the genotype G2554 are thus classified as neuro-
pathogenic [2, 28–31]. However, this classification rather
points to an increased risk of the G2554 strains causing
EHM. During neurological outbreaks between 3 and 45%
of the horses developed EHM [32–34] while non-neuro-
pathogenic strains can also cause neurologic disease [2].
The identification and better characterization of virulence
factors underlying the pathogenicity, immune modulation,
and establishment of latency by EHV-1 can enable targeted
approaches to develop a vaccine providing advanced pro-
tection from the virus.
In vitro infection of equine peripheral blood mononuclear
cells (PBMC) with the non-neuropathogenic EHV-1 strain
RacL11 reduced the down-regulation of MHC class I ex-
pression [35], and increased interleukin10 (IL-10) secretion
[36] and chemokine expression [37] compared to infection
with the neuropathogenic strain Ab4. These findings point
to differences of EHV-1 strains in modulating the host im-
mune response, which may also be relevant in vivo. Poten-
tial virulence factors of the Ab4 strain are the ORF1 and
ORF2 gene products. ORF1 and ORF2 genes are absent in
RacL11, the RacL11-derived modified-live vaccine strain
RacH [38], as well as in the apathogenic strain KyA [39, 40].
Hence, the ORF1 and ORF2 genes could encode for immu-
nomodulatory proteins leading to differences in virulence or
pathogenicity. The ORF1 gene product pUL56 of Ab4 is re-
sponsible for MHC class I down-regulation and seems to be
involved in the suppression of cytokine expression and che-
mokine secretion in vitro [35, 41]. The ORF2 gene is related
to ORF1, but is less well characterized. The ORF2 gene
product was classified as a membrane protein due to its pre-
dicted hydrophobic profile [40]. The deletion of ORF1 and
ORF2 genes from EHV-1 Ab4 significantly reduced pyrexia
duration and viral shedding compared to the parent Ab4
virus in experimentally infected ponies [42]. This effect could
be attributed to either gene or the combination of ORF1 and
ORF2.
Here, we performed an experimental infection in
horses using a single ORF2 gene deletion mutant of the
EHV-1 strain Ab4, Ab4ΔORF2 [35], in comparison to
the parent Ab4 virus. The goals of the approach were to
identify ORF2 as a potential virulence factor, to characterize
the effects of ORF2 on EHV-1 infection and immune re-




Twenty-four horses from the Cornell University herd of
Icelandic horses with known EHV-1 status were enrolled
in this study [43, 44]. All horses were offspring of one stal-
lion, were born at Cornell University, and kept at an iso-
lated facility as a group from birth. They had no contact
with other horses in the USA prior to and for the duration
of this study. All horses were previously experimentally in-
fected with the EHV-1 strain NY03 after weaning at
7 months of age [44, and unpublished data]. By the time
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of the present study, the horses were 2–4 years of age and
their EHV-1 specific immunity had waned to values typic-
ally observed in EHV-1 susceptible horses. EHV-1 specific
protective immunity is short-lasting and believed to be
maintained for 6–9 months after a single experimental in-
fection [27]. The horses were vaccinated annually against
rabies, tetanus, West Nile virus, Eastern and Western En-
cephalitis virus. They were also dewormed twice a year.
Prior to the EHV-1 infection described here, the horses
were kept on pasture and were clinically healthy. Grass
hay was fed to the horses ad libitum. All horses survived
and were kept for research purposes at Cornell University
after the study.
Virus preparation
Viruses for experimental infection were EHV-1 Ab4, a
neuropathogenic strain isolated from a quadriplegic mare
[9, 28, 45] and its ORF2 gene deletion mutant, Ab4Δ
ORF2, produced by two-step Red-mediated recombination
of a recombinant BAC Ab4 as previously described in de-
tail [35]. The viruses were propagated in rabbit kidney
cells (RK13) in MEM medium supplemented with
0.292 g/l L-glutamine, 1 mM sodium pyruvate, 100 U/ml
Penicillin, 100 μg/ml Streptomycin, 50 μg/ml gentamycin,
(all Thermo Fisher Scientific Waltham, MA, USA), and
10% FCS (Atlanta biological, Flowery Branch, GA, USA).
Virus titers were determined in RK13 cells as previously
described [22, 37].
The identity of each virus preparation was confirmed
by conventional PCR on 2 μg of extracted viral DNA,
using primers flanking the ORF1 and ORF2 gene region
of the EHV-1 strain Ab4: forward primer − 5’-AACA
ACCCTGGGCTCTTTA -3′ and reverse primer – 5’-G
ATTCGCACCTCATCTCCAC -3′. The resulting PCR
products had a distinct size of 2043 bp for Ab4 and of
1446 bp for Ab4ΔORF2. The deletion of ORF2 in Ab4Δ
ORF2 was furthermore confirmed by sequencing of the
PCR product at the Biotechnology Core Facility of Cor-
nell University. After infection, the titer of each virus
preparation was confirmed by titration on a plaque assay
as described below.
Experimental EHV-1 infection
For experimental EHV-1 infection horses were assigned
to three groups of eight horses each with four mares and
four geldings per group. One group of horses served as
non-infected controls (control group) and had a median
age of 2 years (range 2–3 years). Horses in a second
group were infected with the neuropathogenic EHV-1
strain Ab4 (Ab4 group) and had a median age of
2.5 years (range 2–3 years). The third group was infected
with the Ab4ΔORF2 deletion mutant virus (Ab4ΔORF2
group) and had a median age of 2.5 years (range 2–
4 years).
One day prior to EHV-1 infection the horses were
moved into the isolation barns with individual box stalls
and allowed to acclimate. The stalls did not allow the
horses to have direct nose-to-nose contact. The non-in-
fected control group was housed in a separate barn and
always handled prior to the other groups. The two in-
fected groups were housed in a barn with two separate
sections, one for each group, divided by a barrier. Air-
flow between sections was not possible. Each section
had a separate entry with an area for donning personal
protective equipment including disposable coveralls,
boots, hats, and gloves. Biosecurity precautions were
taken and people changed personal protective equip-
ment upon entering and exiting each of the sections to
prevent the spread of viruses between the three groups.
Within each barn section, the barn had a center hallway
with the same airspace and horses were handled in each
section as one group. No other specific care was taken
to prevent spread of virus from horse-to-horse within
each group by animal handlers except for changing
gloves after taking nasal swab samples from each horse.
Baseline serum and nasopharyngeal secretion (NS) sam-
ples were taken the day before EHV-1 infection (d-1).
Baseline physical examination measurements were taken
on d-1 and again immediately before EHV-1 infection on
d0. Then, Ab4 group horses were infected intranasally
with 1 x 107 plaque-forming units (PFU) of EHV-1 strain
Ab4 in 4 ml of saline with a mucosal atomizer device
(Wolfe Tory Medical, Salt Lake City, UT). Horses in the
Ab4ΔORF2 group received 1x107 PFU of the Ab4ΔORF2
virus in 4 ml saline intranasally. Horses in the control
group received 4 ml saline without any virus using the
mucosal atomizer device.
Clinical examination
Rectal temperatures were recorded on d-1, twice daily
from d0 until d10 post infection (pi) and then daily on
days 11 to 14 pi. Fever was defined as body temperatures
exceeding 101.5 °F (38.6 °C). Clinical scores were re-
corded daily between d-1 and d14 pi by veterinarians ac-
cording to the grade of depression (0–3), reduced
appetite (0–2), nasal discharge (0–6), eye discharge (0–
3), mandibular lymph node swelling (0–3) and ataxia
(0–5). To determine ataxia, neurologic examinations
were performed as previously described [46]. The gait
was evaluated by walking the horses individually in the
aisle, including turns to both sides. A summarized clin-
ical score for each horse and day was calculated as the
sum of the scores (possible range 0–22). Due to the
housing arrangement examiners were aware of the iden-
tity of the control group, but blinded to the identifica-
tion of the Ab4 or Ab4ΔORF2 groups. The control
group was always worked with first.
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Sample collection and processing
The horses were assigned randomized ID numbers, which
did not reveal the group affiliation to the laboratory
personnel. Samples were processed based on ID numbers
and the group affiliation remained blinded until data col-
lection and assay evaluation was completed.
NS were acquired on d-1, and d1-d9 pi using two
polyester tipped applicators (Puritan Medical Products
Company, Gullford, Maine, USA) swabbed on the nasal
mucosa of one nostril for 5 s. Swabs were immediately
put into 1 ml of sterile phosphate buffered saline (PBS)
in a polystyrene tube. The swabs (in PBS) were trans-
ported to the laboratory, maintained at 4 °C and proc-
essed within 2 hours after sampling. For virus isolation,
NS samples were not further processed. For the analysis
of intranasal cytokines and antibodies, NS samples were
spun at 1000×g at 4 °C for 5 min leaving the swabs in
the collection tube. The diluted NS surrounding the
swabs was collected into a 1.5 ml centrifuge tube and
the cleared fluid supernatant was stored at − 20 °C until
analysis.
Blood samples were collected on d-8, d-1, d1 to d14,
d24, d60, d100, d130, d170, d220, and d260 pi by jugular
venipuncture with a vacutainer system (20G Monoject
Covidien, Medtronic Minneapolis, MN, USA) into glass
tubes without anticoagulant or with sodium heparin
(both BD, Franklin Lakes, NJ, USA). Serum and heparin-
ized blood samples were processed as described previ-
ously [43, 44].
Within 3 h after blood collection PBMC were isolated
by density gradient centrifugation (Ficoll-Paque Plus, GE
Healthcare, Piscataway, NJ, USA) and re-suspended in
cell culture media (DMEM supplemented with 1% (v/v)
non-essential amino acids, 2 mM L-glutamine, 50 μM
2-mercaptoethanol, 50 μg/ml Gentamicin, 100 U/ml
penicillin, 100 μg/ml streptomycin, all from all Thermo
Fisher Scientific Waltham, MA, USA and 10% FCS, At-
lanta biological, Flowery Branch, GA, USA) at 6 × 106
cells/ml for the following experiments. For PCR detec-
tion of viremia, 1 × 107 PBMC were washed twice in
PBS, dry cell pellets were snap frozen in liquid nitrogen,
and stored at − 80 °C until PCR was performed.
Serum samples were stored in aliquots at − 20 °C until
analysis.
Virus isolation
To determine nasal virus shedding virus isolation was per-
formed as plaque assays as previously described [22]. Briefly,
vortexed NS were titrated on confluent RK13 cells. Virus
penetration into the cells was allowed during an incubation
for 2-4 h at 37 °C before supernatants were aspirated and an
overlay with 0.5% Methylcellulose (Sigma Aldrich, St. Louis,
MO, USA) in cell culture medium (Gibco MEM medium,
supplemented with 0.292 g/l L-glutamine, 1 mM sodium
pyruvate, 50 μg/ml Gentamicin, 300 U/ml Penicillin, 300 μg/
ml Streptomycin, 0.75 μg/ml Amphotericin B, all from
Thermo Fisher Scientific and 10% inactivated FCS, Atlanta
biological) was performed. After 5 days of incubation, pla-
ques were counted after fixation and staining in crystal violet
staining solution (PBS containing 4% v/v Paraformaldehyde,
1% v/w Methanol, 0.05% w/v Crystal Violet, all Sigma Al-
drich). Viral titers were expressed as PFU per ml NS.
EHV-1 PCR
Cell associated viremia was evaluated by real-time PCR
targeting the gB gene of EHV-1 performed exactly as
previously described [44, 47]. A total of 1 × 107 PBMC
was used for DNA extraction per horse and time point.
The PCR was performed at the Animal Health Diagnos-
tic Center at Cornell University.
EHV-1 multiplex assay
EHV-1 specific antibodies in serum and NS samples
were determined using a fluorescent bead-based EHV-1
multiplex assay. The assay was previously described in
detail [43] and has been slightly modified for this ap-
proach: Instead of coupling viral glycoproteins directly
to the beads a monoclonal anti-equine IL-4 antibody
(clone 25, [48]) was coupled to all three beads numbered
33, 35 and 36 (Luminex Corp., Austin, TX, USA). Bead
33 was then incubated with IL-4/EHV-1 glycoprotein B
(gB), bead 35 with IL-4/EHV-1 gC, and bead 36 with
IL-4/EHV-1 gD. All three IL-4/EHV-1 glycoproteins
were expressed as described previously [43]. The EHV-1
gB, gC and gD coated beads were then multiplexed, and
incubated with diluted serum (1:400) or undiluted NS
samples, followed by the respective detection antibodies
as described [43]. Total EHV-1 specific immunoglobulin
(Ig) was detected by biotinylated goat anti-horse IgG (H
+ L) antibody (Jackson Immunoresearch Laboratories,
WestGrove, PA, USA). Ig isotype detection was per-
formed by biotinylated monoclonal antibodies specific
for IgG1 (CVS45) and IgG4/7 (CVS39) [both [49]],
IgG1/3 (clone 159–4), IgG3/5 (clone 586), IgG6 (clone
267) [all three [50]], and IgA (BVS2) [51]. Data were re-
ported as median fluorescent intensities (MFI).
Ex vivo re-stimulation of PBMC with EHV-1
EHV-1 re-stimulation of PBMC was performed as previ-
ously described in detail [36, 44, 52]. In brief, PBMC
were re-stimulated ex vivo with EHV-1 strain Ab4 at a
multiplicity of infection of 1 for 48 h. As controls culture
in medium alone or stimulation with Phorbol12-myrista-
te13-acetate (PMA; 25 ng/ml) and ionomycin (1 μM;
both Sigma Aldrich) were included. Supernatants were
collected for the analysis of secreted cytokines. In assays
for intracellular staining of cytokines and flow cytomet-
ric analysis, protein secretion was blocked by Brefeldin
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A (10 μg/ml; Sigma Aldrich) added for the last 24 h of
incubation, before the cells were fixed.
Multiplex assay detection of cytokine secretion
Equine cytokines were quantified in PBMC supernatants,
serum and NS samples using a fluorescent bead-based
multiplex cytokine assay as previously described [53]. Inter-
feron (IFN)-α, IL-4, and IL-10 were reported in pg/ml and
IFN-γ, and IL-17 were reported as U/ml. Furthermore, sol-
uble cluster of differentiation 14 (sCD14), an inflammatory
marker, was determined in serum and NS samples by a sep-
arate bead-based assay as previously described in detail [54]
and was reported in ng/ml. All samples were measured un-
diluted except for the sCD14 analysis in serum. The latter
samples were diluted at 1:200.
EHV-1-specific T-cell detection by flow cytometry
Flow cytometric analysis of EHV-1 specific cells was per-
formed as previously described [43, 44, 52]. In brief, after
EHV-1 re-stimulation PBMC were fixed, permeabilized,
and triple stained for CD4, and CD8 on the cell surface
and intracellular IFN-γ production or intracellular IL-10,
IL-17A, and IL-4, respectively. For each sample 100,000
events were analyzed in a FACS Canto II flow cytometer
(BD Biosciences, San Diego, CA). The evaluation of the
data was performed using FlowJo version 10.2 (FlowJO
LLC, Ashland, OR, USA). A small lymphocyte gate was
set by morphology and the proportions of IFN-γ positive
lymphocytes after re-stimulation, compared to medium
controls were assessed as previously described [52]. The
average intracellular cytokine detection in PMA/ionomy-
cin stimulated PBMC (positive controls) was 14.7% IFN-γ
positive, 2.2% IL-4 positive, 2.2% IL-10 positive, and 0.1%
IL-17 positive lymphocytes.
Statistical analysis
The data sets of this study were not normally distributed
according to D’Agostino and Pearson normality tests. All
data sets were analyzed by repeated measures ANOVA
with Tukey’s Post-hoc test to identify group differences for
each time point analyzed. P-values < 0.05 were considered
significant. Correlation of peak virus shedding and peak
nasal cytokine concentrations were analyzed by two-tailed
Spearman rank correlation. The statistical analysis was
performed using GraphPad Prism software version 6 or
higher (GraphPad Software Inc., La Jolla, CA, USA).
Results
Clinical signs after EHV-1 infection
Horses in both infected groups, Ab4 and Ab4ΔORF2,
displayed clinical signs of mild upper respiratory tract
disease as well as fever, while horses in the control group
did not (Fig. 1a and b). Horses in the Ab4 group devel-
oped an initial fever peak from d1.5 to d2.5 pi, which
was significantly higher than the control group (p <
0.0001). The initial fever peak was less pronounced in
the Ab4ΔORF2 group. Although Ab4ΔORF2 horses had
increased body temperatures compared to the control
group on d1.5 (p < 0.001), d2 and d2.5 pi (both p <
0.0001), the fever in the Ab4ΔORF2 group was lower
than in the Ab4 group on d2 (p < 0.001) and d2.5 pi (p
< 0.01). Afterwards, body temperatures in both infected
groups were significantly increased compared to the
control group at several time points until d5 pi (Fig. 1a).
Horses in the control group had low clinical scores be-
tween 0 and 5 (median 3) resulting from mild nasal or
ocular discharge while stabled. In both infected groups,
nasal discharge and enlarged submandibular lymph
nodes were the most prevalent clinical signs of disease.
Clinical scores in the Ab4 and Ab4ΔORF2 groups were
similar over the course of the study and higher than in
the controls on days 2 to 7 pi (Fig. 1b). Mild signs of
ataxia (score 1) were seen in one horse each in the in-
fected groups. These were noted in the Ab4 group on
days 9 and 10 pi and in the Ab4ΔORF2 group on days 5,
6 and 9 pi, respectively. These symptoms resolved com-
pletely in both horses by d10 pi.
Viral shedding and viremia after EHV-1 infection
Virus was isolated from the NS samples of horses in the
infected groups between d1to d6 pi and peaked on d2 pi
(Fig. 1c). Viral shedding on d2 pi was reduced in
Ab4ΔORF2 infected horses compared to those in the
Ab4 group (p < 0.0001). Although viral shedding was de-
tected in horses of the Ab4ΔORF2 group, their NS virus
amounts were low and not different from the control
group throughout the study. No virus was detected in
NS of the control group.
Cell-associated viremia was detected by PCR. Viral
DNA was detectable in PBMC of both infected groups
and significantly elevated compared to the control group
between days 4 to 8 pi (p < 0.01, Fig. 1d). On d8 pi,
higher amounts of viral DNA were detected in PBMC of
the Ab4ΔORF2 group than in those of the Ab4 group (p
< 0.01) and on d10 pi viral DNA was still elevated in this
group compared to the control group (p < 0.01). Viremia
was not detected in the control group.
Intranasal cytokine production in response to EHV-1
infection
Within the first days after intranasal infection with Ab4 or
Ab4ΔORF2 cytokines were detected in the NS. As the first
cytokine, IFN-α was detected and peaked in both infected
groups at d2 pi, (Fig. 2a) which corresponds with the time
of maximum nasal virus shedding (Fig. 1c). The intranasal
IFN-α concentration of the Ab4 group exceeded that of
the Ab4ΔORF2 group on d2 pi (p < 0.001) and it remained
significantly higher than in the control group on d3 pi (p
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< 0.001). IFN-α concentrations declined to undetectable
values by d4 pi. Intranasal IFN-α was not detected in the
control group.
The inflammatory protein sCD14 increased in NS of
both infected groups starting on d2 pi to peak on d3 pi,
and remained elevated compared to the control group
until d5 pi (Fig. 2b). In Ab4ΔORF2 infected horses
sCD14 was increased on d2 pi in comparison to the con-
trol and Ab4 groups (both p < 0.001), while the peak
sCD14 concentration on d3 pi was higher in Ab4 in-
fected than in Ab4ΔORF2 infected horses (p < 0.05).
Nasal IFN-γ increased as a sharp peak on d3 pi in the
Ab4 and Ab4ΔORF2 groups while it remained undetect-
able in the control group. Differences in IFN-γ values
between the Ab4 and Ab4ΔORF2 infected groups were
not observed (Fig. 2c). At d4 pi IL-10 concentrations
peaked in NS of both infected groups compared to the
control group (p > 0.0001) and declined gradually to
baseline values by d6 pi in the Ab4 or d7 pi in the
Ab4ΔORF2 group. Differences in IL-10 values between
the Ab4 and Ab4ΔORF2 infected groups were not ob-
served (Fig. 2d). Intranasal IL-4 and IL-17 were overall
Fig. 1 Clinical findings and virus detection after experimental infection with the EHV-1 strain Ab4 or its deletion mutant Ab4ΔORF2. Three groups of
horses (n= 8/group) were either not infected (control), infected with the neuropathogenic EHV-1 strain Ab4 (Ab4) or infected with its ORF2 deletion
mutant (Ab4ΔORF2) on day 0 (arrow). Clinical signs were monitored and virus detection was performed before (day − 1) and after infection (day 1 to 14).
Body temperature (a); clinical score calculated as the sum of numerical scores for nasal discharge, ocular discharge, lymph node enlargement, ataxia,
depression and reduced appetite ranging from 0 to 22 (b); viral shedding expressed as plaque forming units (PFU/ml) detected by virus isolation in
nasopharyngeal secretions (c); viremia determined in 1 × 107 PBMC by real time PCR and shown as Ct values for the gB gene (d) were analyzed; Mean and
standard errors are plotted for each group. Dotted horizontal lines represent a cutoff of fever at 101.5 °F (a) and EHV-1 detection at a Ct 38 (D). Significant
differences between groups are marked: a=Ab4 vs. control, b=Ab4ΔORF2 vs. control, c=Ab4 vs. Ab4ΔORF2
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low or not detectable and similar between all three
groups (data not shown).
The maximum values of virus shedding on d2 pi posi-
tively correlated with the peak values of nasal IFN- α
and sCD14 (Table 1).
Antibody response to infection
Antibodies specific for EHV-1 gB, gC, and gD were deter-
mined before and following infection in NS and serum.
The antibody responses to the three EHV-1 antigens were
slightly different in magnitude (gB = gD < < gC) but
followed a similar overall pattern. Thus, representative re-
sults of EHV-1 gC-specific antibodies are presented here.
Total EHV-1 gC-specific Ig in NS and serum were low
before infection (d-8, d-1) in all horses and EHV-1 specific
antibody induction was not detected in the control group
throughout the study (Fig. 3).
Intranasal antibody response to infection
Infection with either virus, Ab4 or Ab4ΔORF2, induced
EHV-1 gC-specific intranasal antibodies following a
wave-like pattern, characterized by several peaks on days
3–4, 10, 24–60, and 130 pi (Fig. 3a). The highest magni-
tude of the anti-gC antibody response was observed at
d24 pi (Ab4ΔORF2 group) or d60 pi (Ab4 group). The in-
crease of total anti-gC antibodies was significantly higher
in both infected groups compared to the control group
from days 8 to 130 pi, and in the Ab4 group also on days
4 and 7 pi. After d170 pi, nasal EHV-1 specific antibodies
in both infected groups returned to low values until the
end of the study period on d260 pi, which were not signifi-
cantly different from the control group. Intranasal
gC-specific antibodies were higher in the Ab4ΔORF2
group than in the Ab4 group on d13 pi (p < 0.01) and d24
pi (p < 0.05), while the Ab4 group exceeded the
Ab4ΔORF2 group on d60 pi (p < 0.05) (Fig. 3a).
The initial intranasal antibody increase on d3-4pi was
composed of low amounts of different gC-specific IgG
Fig. 2 Intranasal cytokine secretion after infection with EHV-1 strain Ab4 or its deletion mutant Ab4ΔORF2. Three groups of horses (n = 8/group) were
either not infected (control), infected with the neuropathogenic EHV-1 strain Ab4 (Ab4) or infected with its ORF2 deletion mutant (Ab4ΔORF2) on day
0 (arrow). Before (day − 1) and after (day 1–24) experimental infection IFN-α (a), sCD14 (b), IFN-γ (c), and IL-10 (d) were quantified in nasopharyngeal
secretions by fluorescent bead-based assays. Mean and standard errors are plotted for each group. Significant differences between groups are marked:
a = Ab4 vs. control, b = Ab4ΔORF2 vs. control, c = Ab4 vs. Ab4ΔORF2
Table 1 Spearman rank correlations of peak nasal cytokines and
sCD14 with maximum virus shedding on day 2 pi
day pi IFN-α sCD14 IFN-γ IL-10
d2 pi d3 pi d3 pi d4 pi
r 0.8066 0.7866 0.6442 0.4860








P value < 0.0001 < 0.0001 0.0007 0.0160
aCI confidence interval
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isotypes, and in the Ab4ΔORF2 group also some IgA
(Fig. 3b-f ). Afterwards, the intranasal anti-gC total
antibody peaks (Fig. 3a) were each dominated by dif-
ferent isotypes. The second anti-gC peak on day 10 pi
corresponded to an increase of primarily IgG1 in both
infected groups (Fig. 3b). IgG1 was induced slightly
earlier (d7, p < 0.001) in the Ab4 than in the Ab4
ΔORF2 group (d8). Similarly, the third anti-gC anti-
body peak on days 24 (Ab4ΔORF2) and 60 pi (Ab4),
respectively, and the fourth peak on d130 pi were
mainly composed of IgG4/7 (Fig. 3c). Anti-gC IgG4/7
antibodies almost mimicked the total anti-gC re-
sponse shown in Fig. 3a from d24 pi on. This
included the higher IgG4/7 in the AbΔORF2 com-
pared to the Ab4 group on d24 pi (p < 0.01), the
lower intranasal IgG4/7 in the AbΔORF2 group on
d60 pi (p < 0.0001), and on d130 pi (p < 0.05) com-
pared to the Ab4 group.
Notably, intranasal gC-specific IgA after infecting
horses with the Ab4 virus was not different from the
control horses at any time after infection. In contrast,
gC-specific IgA was increased in the Ab4ΔORF2
group compared to the control group on days 8, 10
to 12 and 14 pi. It was also higher than in the Ab4
group on d10 and d11 pi (Fig. 3d). Overall the intra-
nasal EHV-1 specific IgA response in the Ab4ΔORF2
Fig. 3 Anti-EHV-1 gC antibodies in nasal secretions after infection with EHV-1 strain Ab4 or its deletion mutant Ab4ΔORF2. Three groups of horses (n=8/
group) were either not infected (control), infected with the neuropathogenic EHV-1 strain Ab4 (Ab4) or infected with its ORF2 deletion mutant (Ab4ΔORF2) on
day 0 (arrow). Before (day − 1) and after (day 1–260) experimental infection EHV-1 gC specific total Ig (a), IgG1 (b), IgG4/7 (c), IgA (d), IgG1/3 (e), and IgG3/5 (f)
were quantified in nasopharyngeal secretions by fluorescent bead-based multiplex assays and expressed as median fluorescent intensities (MFI). Note that Y-
axes scales differ depending on isotype. Mean and standard errors are plotted for each group. Significant differences between groups are marked: a=Ab4 vs.
control, b=Ab4ΔORF2 vs. control, c=Ab4 vs. Ab4ΔORF2
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group appeared to be of low magnitude and short
duration.
EHV-1 gC-specific IgG1/3 induction mimicked IgG1
antibodies until d14 pi (Fig. 3e). IgG3/5 antibodies were
overall low including the early peak on d3pi (Fig. 3f ).
This supports that the IgG1/3 antibody response until
d14 pi was mainly composed of IgG1. On d24 pi, an in-
crease in IgG1/3 antibodies was observed in both in-
fected groups (p < 0.0001). This increase was higher
than the corresponding IgG1 response in Fig. 3b and
likely results from a mixture of anti-gC IgG1 and IgG3
on d24 pi.
EHV-1 specific IgG6 in nasal secretion was low for all
groups throughout the study and no group differences
were observed (data not shown).
Serum antibody response to EHV-1 infection
Infection with either Ab4 or Ab4ΔORF2 resulted in the
induction of EHV-1 gC-specific Ig in serum which was
first increased on d8 pi compared to the control group
(p < 0.01). Anti-gC antibodies peaked on d24 pi, slowly
declined until d170 pi, and then remained constant in
both infected groups for the remainder of the study
(Fig. 4a) with p-values< 0.0001 between days 10 to
Fig. 4 Anti-EHV-1 gC antibodies in serum after EHV-1 infection. Three groups of horses (n = 8/group) were either not infected (control), infected
with the neuropathogenic EHV-1 strain Ab4 (Ab4) or infected with its ORF2 deletion mutant (Ab4ΔORF2) on day 0 (arrow). Before (day − 1) and
after (day 1–260). EHV-1 gC specific total Ig (a), IgG1 (b), IgG1/3 (c), IgG4/7 (d), IgG3/5 (e) and IgG6 (f) were quantified in serum by fluorescent
bead-based multiplex assays and expressed as median fluorescent intensities (MFI). Note that Y-axes scales differ depending on isotype. Mean
and standard errors are plotted for each group. Significant differences between groups are marked: a = Ab4 vs. control, b = Ab4ΔORF2 vs. control,
c = Ab4 vs. Ab4ΔORF2
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260 pi for both infected groups in comparison to the
control group. Total gC-specific Ig was similar between
the Ab4 or Ab4ΔORF2 groups for the duration of the
study and until d260 pi.
In both infected groups, Ab4 and Ab4ΔORF2, IgG1
(Fig. 4b) and IgG1/3 isotypes (Fig. 4c) were detectable
early after infection. They peaked on d10 or d12 pi and
declined by d60 pi to baseline values. In the Ab4 group,
IgG1 and IgG1/3 induction was slightly earlier than in
the Ab4ΔORF2 group (d8 vs. d10) and reached higher
IgG1 values on d10 pi (p < 0.05).
Anti-gC IgG4/7 antibodies were first detectable on
d10 pi in both infected groups and peaked on d24 pi.
IgG4/7 primarily contributed to the long-term EHV-1
specific antibody response with both infected groups ex-
ceeding the antibody values of the control group from
d10 until d260 pi (p-values between p < 0.0001 and p <
0.05) (Fig. 2d). Differences in the IgG4/7 response of the
Ab4 and Ab4ΔORF2 groups were not observed.
EHV-1 specific IgG3/5 was weakly induced and ele-
vated in comparison to the control group in the Ab4
group on days 8 to 14 pi (p < 0.05 to p < 0.001), and in
the Ab4ΔORF2 group on d12 and d14 pi (both p < 0.05)
(Fig. 4e). IgG6 was present in low quantities, which were
increased compared to the control group in the Ab4 and
Ab4ΔORF2 group on days 10–60 pi (p < 0.05). On days
24 and 60 pi the IgG6 antibodies in the Ab4ΔORF2
group exceeded those in the Ab4 group (both p < 0.05)
(Fig. 4f ). EHV-1-specific IgA was not detected in serum
at any time point (data not shown).
Cellular immune response to EHV-1
Cellular immune responses of all groups were analyzed
by ex vivo re-stimulation of PBMC with the EHV-1
strain Ab4. Between 5 and 10 days pi, IFN-γ secretion
was elevated in horses of both the Ab4 group (days 5, 6,
8 pi, p < 0.05) and the Ab4ΔORF2group (days 6, 10 pi, p
< 0.05) (Fig. 5a) compared to the control group. The
IL-10 secretion displayed a similar biphasic response
with the IL-10 peak on d5 pi slightly preceding the max-
imal IFN-γ response on d6pi. Both infected groups had
greater IL-10 secretion from re-stimulated PBMC on
days 5 and 6 pi (p < 0.05), and IL-10 was again elevated
at d8 pi in the Ab4 group (p < 0.01) while the
Ab4ΔORF2 group had a non-significant trend at d8 pi
(Fig. 5b) compared to the control group. At later time
points (d60-d260 pi) induction of cytokine secretion
from PBMC in response to ex vivo re-stimulation was
not observed for any group. Significant IL-4 and IL-17
secretion was not induced at any time (data not shown).
Secretion of IFN-α was induced by the in vitro infection
of PBMC at all time points, but there was no difference
between the three groups of horses during the study
(data not shown).
In addition, EHV-1 specific T-cells were analyzed by
flow cytometry for intracellular IFN-γ, IL-4, IL-10 and
IL-17 production. IFN-γ production by lymphocytes in
PBMC were overall low and not different between the
three groups for the duration of the study (Fig. 5c). IL-4,
IL-10 or IL-17 were not induced in lymphocytes after ex
vivo re-stimulation with EHV-1 (data not shown).
Cytokine responses in serum
Cytokine measurements in serum were overall similar
between the control and the infected groups with a few
exceptions. IFN-α was increased in serum early after in-
fection on days 2 and 4 pi in the Ab4ΔORF2 group com-
pared to the control group (p < 0.05, Additional file 1:
Figure S1A). In the Ab4 group there was a non-signifi-
cant trend of increased serum IFN-α on d2 pi. It
remained at a similar level to uninfected controls for the
remainder of the measurements in both infected groups.
Serum sCD14 was elevated in the Ab4 group compared
to the control group at d3 pi (p < 0.01). In addition,
sCD14 was higher in the control group compared to the
Ab4ΔORF2 group at d13 pi (p < 0.05) but was increased
in the Ab4ΔORF2 group compared to both, Ab4 and the
controls at d24 pi, while it was still significantly higher
in Ab4 than in controls at that day (p < 0.05, Additional
file 1: Figure S1B). The levels of serum IFN-γ did not
differ between the three groups at any point during the
experiment (Additional file 1: Figure S1C). IL-4 and
IL-17 concentrations were overall low in serum and
without any differences between the three groups (data
not shown).
Discussion
An experimental infection with Ab4ΔORF2 deletion mu-
tant virus in comparison to the parental neuropatho-
genic Ab4 virus was performed in horses to characterize
the effects of the ORF2 gene product on EHV-1 infec-
tion and host immunity. Clinical signs, nasal shedding,
and viremia induced by both viruses were evaluated to
identify differences in virulence. Host immunity was an-
alyzed locally and systemically summarizing the influ-
ence of both viruses on innate and adaptive cellular
immunity and antibody induction. Overall, the infection
of the horses with the parent Ab4 strain in the present
study induced similar clinical signs, virus shedding, and
viremia as previously described for EHV-1 infections of
susceptible hosts [14, 42, 55]. Most importantly, the de-
letion of ORF2 reduced the virulence of the neuropatho-
genic EHV-1 Ab4 virus. This was evident by clearly
reduced magnitude of the initial fever and significantly
lower viral shedding in horses infected with the Ab4
ΔORF2 deletion mutant virus. The reduced virulence
observed here for Ab4ΔORF2 was comparable to the
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shorter duration of pyrexia, decreased magnitude and
duration of virus shedding but unaffected viremia after
infection of ponies with Ab4ΔORF1/2 compared to Ab4
in an earlier approach [42]. Differences in the magnitude
of the fever induced by Ab4 infection may be based on
individual differences between the ponies used by Soboll
et al. [42] and the Icelandic horses used in the present
study. Importantly, the reduction of virus shedding after
deleting the ORF2 gene from the Ab4 virus versus using
an Ab mutant deprived of ORF1 and ORF2 in the previ-
ous study [42] should be directly compared: Soboll et al.
quantified EHV-1 DNA by PCR, while we used a plaque
assay for virus isolation from nasal secretion, which
measures infectious virus and thus correlates more dir-
ectly with viral shedding and the ability of the infected
horse to infect other horses.
The virulence factor ORF2 impacted the infection of the
upper respiratory tract and local innate immune response
to EHV-1 infection. In this study, we provided a compre-
hensive evaluation of intranasal cytokine and antibody se-
cretion to longitudinally describe local innate and adaptive
host immune responses during EHV-1 infection and poten-
tial differences induced by the ORF2 gene product. The on-
set of the local innate immune response against Ab4 was
observed during virus shedding as determined by isolation
of infectious virus from nasal discharge on days 2–4 pi. In-
tranasal innate immunity was characterized by sequential
increases of the cytokines IFN-α (peak on d2pi), IFN-γ
(peak on d3pi), and IL-10 (peak on d4pi) followed by a
quick decline of all three cytokines. The nasal secretion of
bioactive IFN was correlated with the time of EHV-1 shed-
ding in a prior experimental infection study by Edington
[56]. Here, we identified that high IFN-α in nasal secretion
positively correlates with EHV-1 shedding in the Ab4 in-
fected horses. In comparison, Ab4ΔORF2 infection induced
low viral shedding combined with decreased IFN-α secre-
tion. It has been demonstrated earlier, that equine IFN-α
detected by the mAb pair used for quantification here, is
also bioactive [57]. This suggests that intranasal IFN-α
Fig. 5 Cellular immune responses to infection in PBMC. Three groups of
horses (n=8/group) were either not infected (control), infected with the
neuropathogenic EHV-1 strain Ab4 (Ab4) or infected with its ORF2 deletion
mutant (Ab4ΔORF2) on day 0 (arrow). PBMC were isolated before (day − 1)
and after infection (day 1–24) and re-stimulated ex vivo for 48 h with EHV-
1 (strain Ab4). Cytokine production (a and b) was analyzed in supernatants
by a fluorescent bead-based multiplex assay. All values are cell culture
medium control corrected. Mean and standard errors of secreted IFN-γ (a)
and IL-10 (b) are shown. EHV-1 stimulated PBMC were also fixed, stained
for intracellular IFN-γ and analyzed by flow cytometry. Total EHV-1 specific
IFN-γ producing lymphocytes are displayed (c). Values have been corrected
by the respective medium control of each horse. The dotted horizontal
line (c) represents a cutoff of 0.1% IFN-γ+ lymphocytes. PBMC controls
kept in medium alone typically result in values below this cutoff value.
Significant differences between groups are marked: a=Ab4 vs. control, b
=Ab4ΔORF2 vs. control, c=Ab4 vs. Ab4ΔORF2
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serves as an early danger signal during EHV-1 infection
and, as previously pointed out by Randall [58], likely sup-
ports the induction of an antiviral state in the infected mu-
cosal tissues. Notably, local IFN-γ and IL-10 induction was
similar in both infected groups, Ab4ΔORF2 and Ab4, indi-
cating that the ORF2 gene product does not influence these
two immune regulatory cytokines.
Besides the short-term and pointed IFN-α, IFN-γ, and
IL-10 secretion, elevated sCD14 concentrations were lo-
cally induced by EHV-1 between days 2–5 pi, while the
horses were shedding virus. Peak intranasal sCD14 con-
centrations were slightly reduced in Ab4ΔORF2 infected
horses supporting a possible direct or indirect influence
of the ORF2 gene on intranasal sCD14 secretion. Lipo-
polysaccharide (LPS) binding sCD14 is produced by exo-
cytosis and shedding of CD14 from monocyte or
macrophage cell surfaces [59–61] and has a neutralizing,
anti-inflammatory role for protection against LPS-induced
cell death [62, 63]. The exact mechanisms of sCD14 in-
duction after EHV-1 infection still needs to be unraveled
in future approaches. However, EHV-1 was described to
infect monocytes in vitro and in vivo [7, 64, 65] and the
nasal sCD14 increase could thus result from a stress
response of EHV-1 infected macrophages of the upper re-
spiratory tract or reflect responses related to phagocytosis
of virus and infected cells.
Overall, these findings point towards a role of ORF2 in
the lytic virus replication cycle in the nasopharyngeal
epithelia, which supported the release of infectious vi-
rions and increased the local viral load and nasal shed-
ding. Nevertheless, the transmission of EHV-1 to
mononuclear cells resulting in cell-associated viremia [7,
66] appears to be independent of ORF2. Here, viremia in
the Ab4ΔORF2 and Ab4 groups was similar. Addition-
ally, in vitro replication of Ab4ΔORF2 or Ab4ΔORF1/2
in RK13 cells and equine dermal cells (NBL-6) was not
impaired compared to Ab4 [42]. Thus, the impact of
ORF2 on nasal virus replication can only be shown after
in vivo infection of the mucosal epithelial tissue includ-
ing an intact local innate immune response.
In contrast to the clear reduction of virulence and intra-
nasal IFN-α and sCD14 secretion, the immunogenicity of
EHV-1 was not influenced by the deletion of the ORF2
gene from Ab4, with the only exception of a slightly earlier
onset of IgG1 antibody responses in serum and during the
second intranasal IgG1 peak in Ab4 infected horses. Local
EHV-1 specific antibodies were detectable intranasally
within 3–4 days after infection at low values. At this time,
antibody responses were not yet detectable in serum. This
very early nasal Ig secretion was similarly composed of dif-
ferent IgG isotypes and seems to be derived from local
cells, such as lamina propria memory B-cells or those lo-
cated in the regional lymph nodes. It should again be
pointed out that all horses in this study were infected with
EHV-1 about 1.5 to 2.5 years prior to the EHV-1 infection
performed here. This confirmed the transient nature of
protective immunity to EHV-1 described earlier [3, 27].
Although our horses did not mount a rapid and suffi-
ciently high immune response to be protected from the
EHV-1 infection performed here, they likely still had
EHV-1 specific memory B-cells in their lymphatic tissues.
Binding of viral antigens may have stimulated these mem-
ory B-cells to quickly secrete EHV-1 specific antibodies in
low, but detectable quantities 3–4 days after infection.
Interestingly, this initial local IgG response waned
quickly and was followed by peaks of higher local anti-
body responses that were dominated by IgG1 between
d8–12 pi and IgG4/7 after d14 pi. Our findings clearly
indicate that mucosal immune responses against the
EHV-1strain Ab4 are dominated by IgG antibodies. In-
tranasal EHV-1 specific IgG antibodies are secreted in
waves for several months post infection. The reason for
the wave-like local antibody pattern is not yet clear. It
requires further evaluation to identify if they could re-
flect local subclinical EHV-1 re-activation stages or other
mechanisms. In contrast, the nasal EHV-1 specific IgA
response after Ab4 infection was of overall low magni-
tude with slightly higher values for some horses that
were infected with Ab4ΔORF2 during d8–14 pi. EHV-1
specific IgA was not detectable at later time points sup-
porting that IgA is neither a major nor a long-lasting
antibody during the mucosal EHV-1 specific immune re-
sponse. This finding is contradictory to Breathnach [67],
who found significant induction of nasal EHV-1 specific
IgA together with IgG isotypes 2 weeks after primary in-
fection with the neuropathogenic EHV-1 strain Army
183. Both, Breathnach [67] and our analysis here were
based on the same monoclonal IgA antibody, BVS2, but
used different assays for antibody detection. Future re-
search could analyze if the observed difference in the
EHV-1 specific IgA response are related to viral strain
differences or if they have other reasons.
Robust systemic EHV-1 specific antibody responses were
found in serum by d8 pi and were still detectable at high
values by 9 months after infection with Ab4 or Ab4ΔORF2.
Similar to nasal secretions, IgG1 was the dominating iso-
type of the early systemic response to EHV-1 infection,
while IgG4/7 maintained the long-term response for more
than 9 months. Similar serum antibody kinetics and IgG
isotypes were previously reported after experimental
EHV-1 infection with different EHV-1 strains including
Ab4 and NY03 [42, 44]. This report exceeds the longitu-
dinal observation period of previous articles of monitoring
the immune response for weeks [67, 68] to 2–3 months
[42, 69] after EHV-1 infection.
The glycoproteins gC and gD of EHV-1 are entry recep-
tors of EHV-1 and highly immunogenic [70, 71]. In
horses, gC and gD specific serum Ig and IgG4/7 highly
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correlate with EHV-1 serum neutralization titers [43].
Here, EHV-1 gC and gD specific antibodies were mea-
sured as representative markers for local and systemic
EHV-1 specific immune responses with anti-gD responses
closely resembling those of anti-gC. Equine IgG1 and
IgG4/7 antibodies expressed effector functions such as
strong complement activation and a high affinity to bind
to IgG Fc-receptors in vitro [72]. EHV-1 specific IgG1 and
IgG4/7 were thus assumed to have neutralizing activity
and mediate protection against EHV-1 infection [22, 52].
Furthermore, IgG1 and IgG4/7 have been associated with
a Th1 dominated B-cell response against EHV-1 [43].
In contrast to the robust antibody induction, an
EHV-1 specific T-cell response could not be detected
after infection with Ab4 or Ab4ΔORF2. Similarly, only
weak T-cell responses were observed in former studies
after experimental infection with EHV-1 Ab4 or NY03
[42, 44, 69]. However, we and others demonstrated in-
creased EHV-1 specific cytotoxic T-cells frequencies or
IFN-γ producing T-cells during viremia in older horses
[13, 73], a few weeks after infection [74–76], or in horses
that experienced an EHM outbreak and several vaccina-
tions afterwards [52]. This suggests that EHV-1 specific
T-cell activation is not consistently observed after infec-
tion, can be a slow process, and may require several im-
mune recognition and activation events with EHV-1 or
an EHV vaccine to develop substantial EHV-1 specific
T-cell immunity. In the present study, a detectable cellular
response was limited to EHV-1 re-stimulation ex vivo, oc-
curred during viremia, and was represented by increased
secretion of IL-10 and IFN-γ from PBMC. Likely, the tran-
sient stimulations of cytokine secretion from PBMC re-
sulted from an innate response to the viral infection of
circulating immune cells. It is believed that EHV-1
down-regulates cellular immunity and thereby allows the
establishment of cell-associated viremia, which is a pre-
requisite for infection of endothelial cells prior to develop-
ing EHM or abortions [27, 66]. Current modified-live
vaccines containing deletions of ORF2 and other genes
[38, 40], similar to Ab4ΔORF2, fail to induce T-cell im-
munity and thus do not prevent viremia [22, 23, 52]. The
EHV-1 genes responsible for the down-regulation of T-cell
immunity still need to be identified to achieve robust cel-
lular host immunity against EHV-1.
Conclusions
The ORF2 gene of the EHV-1 strain Ab4 is a virulence
factor which contributes to fever and viral shedding but
does not affect viremia or adaptive host immunity against
the virus (Graphical abstract). Infection with EHV-1 Ab4
and its ORF2 deletion mutant induces high local and sys-
temic antibody responses dominated by early IgG1 and
long-lasting IgG4/7 isotypes. Local EHV-1 specific IgA
antibodies are only a minor component of the mucosal
immune response. Antibody responses dominate EHV-1
immunity while T-cell immunity is overall low.
Additional file
Additional file 1: Figure S1. Cytokines in serum after infection with EHV-1
strain Ab4 or its deletion mutant Ab4ΔORF2. Horses (n=8/group) were infected
with one of two EHV-1 strains (Ab4) or Ab4ΔORF2 at day 0 or kept as uninfected
controls. Serum was sampled at several times before (days − 8, − 1) and after
(day 1- day 24) infection, cytokines and the inflammatory marker sCD14 were
evaluated with fluorescent bead-based assays. Mean and standard errors for IFN-
α (A), sCD14 (B), and IFN-γ (C) in the serum are displayed. Significant differences
between groups are marked: a =Ab4 vs. control, b = Ab4ΔORF2 vs. control,
c =Ab4 vs. Ab4ΔORF2. (JPG 332 kb)
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